Cargando…
Inhibitor Risk Stratification and Individualized Treatment in Patients With Nonsevere Hemophilia A: A Single-Institution Practice Audit
Inhibitor risk in nonsevere hemophilia A increases with cumulative factor VIII (FVIII) exposure days and high-risk mutations. A standardized approach to minimize inhibitor risk is warranted. Following establishment of a systematic approach to reduce inhibitor risk in nonsevere hemophilia, we evaluat...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6714690/ https://www.ncbi.nlm.nih.gov/pubmed/29108420 http://dx.doi.org/10.1177/1076029617737836 |
_version_ | 1783447104629243904 |
---|---|
author | Sun, Haowei (Linda) Chan, Stella Yenson, Paul Jackson, Shannon |
author_facet | Sun, Haowei (Linda) Chan, Stella Yenson, Paul Jackson, Shannon |
author_sort | Sun, Haowei (Linda) |
collection | PubMed |
description | Inhibitor risk in nonsevere hemophilia A increases with cumulative factor VIII (FVIII) exposure days and high-risk mutations. A standardized approach to minimize inhibitor risk is warranted. Following establishment of a systematic approach to reduce inhibitor risk in nonsevere hemophilia, we evaluated the uptake of these strategies into clinical practice. All adult males with nonsevere hemophilia A followed by British Columbia Adult Hemophilia Program from 2004 to 2016 were included in this retrospective audit. Quality-of-care indicators on inhibitor prevention were examined. Of 108 patients, 18 patients had high-risk FVIII mutations for inhibitor development. Rates of FVIII genotyping and 1-deamino-8-d-arginine-vasopressin (DDAVP) testing in mild patients without contraindications were both over 90%, although DDAVP was used for surgical prophylaxis in only 70% of procedures. Inhibitor testing and clinic visits occurred at a median interval of 22 months. Over 80% of patients with high-risk mutations had documentation and education on their inhibitor risk. Our practice audit demonstrated a high level of recognition and patient education of individual inhibitor risk. Impact of our standardized approach on the incidence of inhibitor development is yet to be determined. |
format | Online Article Text |
id | pubmed-6714690 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-67146902019-09-04 Inhibitor Risk Stratification and Individualized Treatment in Patients With Nonsevere Hemophilia A: A Single-Institution Practice Audit Sun, Haowei (Linda) Chan, Stella Yenson, Paul Jackson, Shannon Clin Appl Thromb Hemost Original Articles Inhibitor risk in nonsevere hemophilia A increases with cumulative factor VIII (FVIII) exposure days and high-risk mutations. A standardized approach to minimize inhibitor risk is warranted. Following establishment of a systematic approach to reduce inhibitor risk in nonsevere hemophilia, we evaluated the uptake of these strategies into clinical practice. All adult males with nonsevere hemophilia A followed by British Columbia Adult Hemophilia Program from 2004 to 2016 were included in this retrospective audit. Quality-of-care indicators on inhibitor prevention were examined. Of 108 patients, 18 patients had high-risk FVIII mutations for inhibitor development. Rates of FVIII genotyping and 1-deamino-8-d-arginine-vasopressin (DDAVP) testing in mild patients without contraindications were both over 90%, although DDAVP was used for surgical prophylaxis in only 70% of procedures. Inhibitor testing and clinic visits occurred at a median interval of 22 months. Over 80% of patients with high-risk mutations had documentation and education on their inhibitor risk. Our practice audit demonstrated a high level of recognition and patient education of individual inhibitor risk. Impact of our standardized approach on the incidence of inhibitor development is yet to be determined. SAGE Publications 2017-11-06 2018-03 /pmc/articles/PMC6714690/ /pubmed/29108420 http://dx.doi.org/10.1177/1076029617737836 Text en © The Author(s) 2017 http://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Original Articles Sun, Haowei (Linda) Chan, Stella Yenson, Paul Jackson, Shannon Inhibitor Risk Stratification and Individualized Treatment in Patients With Nonsevere Hemophilia A: A Single-Institution Practice Audit |
title | Inhibitor Risk Stratification and Individualized Treatment in Patients With
Nonsevere Hemophilia A: A Single-Institution Practice Audit |
title_full | Inhibitor Risk Stratification and Individualized Treatment in Patients With
Nonsevere Hemophilia A: A Single-Institution Practice Audit |
title_fullStr | Inhibitor Risk Stratification and Individualized Treatment in Patients With
Nonsevere Hemophilia A: A Single-Institution Practice Audit |
title_full_unstemmed | Inhibitor Risk Stratification and Individualized Treatment in Patients With
Nonsevere Hemophilia A: A Single-Institution Practice Audit |
title_short | Inhibitor Risk Stratification and Individualized Treatment in Patients With
Nonsevere Hemophilia A: A Single-Institution Practice Audit |
title_sort | inhibitor risk stratification and individualized treatment in patients with
nonsevere hemophilia a: a single-institution practice audit |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6714690/ https://www.ncbi.nlm.nih.gov/pubmed/29108420 http://dx.doi.org/10.1177/1076029617737836 |
work_keys_str_mv | AT sunhaoweilinda inhibitorriskstratificationandindividualizedtreatmentinpatientswithnonseverehemophiliaaasingleinstitutionpracticeaudit AT chanstella inhibitorriskstratificationandindividualizedtreatmentinpatientswithnonseverehemophiliaaasingleinstitutionpracticeaudit AT yensonpaul inhibitorriskstratificationandindividualizedtreatmentinpatientswithnonseverehemophiliaaasingleinstitutionpracticeaudit AT jacksonshannon inhibitorriskstratificationandindividualizedtreatmentinpatientswithnonseverehemophiliaaasingleinstitutionpracticeaudit |